Cocrystal Pharma, Inc. – NASDAQ:COCP
Founder-led company
Cocrystal Pharma stock price today
$1.532
-1.55
-50.43%
Financial Health
0
1
2
3
4
5
6
7
8
9
Market closed
Open in 2 days
Cocrystal Pharma stock price monthly change
+34.35%
month
Cocrystal Pharma stock price quarterly change
+34.35%
quarter
Cocrystal Pharma stock price yearly change
+75.57%
year
Cocrystal Pharma key metrics
Market Cap | 22.68M |
Enterprise value | N/A |
P/E | -0.43 |
EV/Sales | N/A |
EV/EBITDA | 0.27 |
Price/Sales | N/A |
Price/Book | 0.46 |
PEG ratio | N/A |
EPS | -1.65 |
Revenue | N/A |
EBITDA | -23.28M |
Income | -16.75M |
Revenue Q/Q | N/A |
Revenue Y/Y | N/A |
Profit margin | 0% |
Oper. margin | 0% |
Gross margin | 0% |
EBIT margin | 0% |
EBITDA margin | N/A |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeCocrystal Pharma stock price history
Cocrystal Pharma stock forecast
Cocrystal Pharma financial statements
| Jun 2023 | 0 | -4.16M | |
|---|---|---|---|
| Sep 2023 | 0 | -4.16M | |
| Dec 2023 | 144K | -4.46M | -3100% |
| Mar 2024 | 0 | -3.95M |
| Mar 2024 | 0 | -3.95M | |
|---|---|---|---|
| Sep 2025 | 54.95K | -3.45M | -6294.19% |
| Oct 2025 | 0 | -4.17M | |
| Dec 2025 | 0 | -4.01M |
Analysts Price target
Financials & Ratios estimates
| Jun 2023 | 36279000 | 1.59M | 4.4% |
|---|---|---|---|
| Sep 2023 | 32614000 | 1.92M | 5.9% |
| Dec 2023 | 31259000 | 4.87M | 15.6% |
| Mar 2024 | 26546000 | 3.96M | 14.92% |
| Jun 2023 | -5.54M | -14K | 4K |
|---|---|---|---|
| Sep 2023 | -2.68M | -1.54K | 104.47K |
| Dec 2023 | -2.86M | -57.00K | -174.36K |
| Mar 2024 | -4.50M | -8K | 0 |
Cocrystal Pharma alternative data
| Aug 2023 | 12 |
|---|---|
| Sep 2023 | 12 |
| Oct 2023 | 12 |
| Nov 2023 | 12 |
| Dec 2023 | 12 |
| Jan 2024 | 12 |
| Feb 2024 | 12 |
| Mar 2024 | 12 |
| Apr 2024 | 12 |
| May 2024 | 12 |
| Jun 2024 | 12 |
| Jul 2024 | 12 |
Cocrystal Pharma other data
3.86%
-14.09%
of COCP is owned by hedge funds
229.41K
-836.75K
shares is hold by hedge funds
What is insider trading?
| Period | Buy | Sel |
|---|---|---|
| Apr 2023 | 1015229 | 0 |
| Transaction | Date | Insider | Security | Shares | Price per share | Total value | Source |
|---|---|---|---|---|---|---|---|
Purchase | FROST PHILLIP MD ET AL director, 10 perc.. | Common Stock | 1,015,229 | $1.97 | $2,000,001 | ||
Purchase | FROST PHILLIP MD ET AL director, 10 perc.. | Common Stock | 1,015,229 | $1.97 | $2,000,001 | ||
Purchase | PFENNIGER RICHARD C JR director | Common Stock | 40,000 | $1.03 | $41,120 | ||
Sale | SCHINAZI RAYMOND F 10 percent owner | Common Stock | 575,000 | $2.95 | $1,696,250 | ||
Purchase | SCHINAZI RAYMOND F 10 percent owner | Common Stock | 7,906 | $1.15 | $9,092 | ||
Purchase | SCHINAZI RAYMOND F 10 percent owner | Common Stock | 5,094 | $1.15 | $5,858 | ||
Purchase | SCHINAZI RAYMOND F 10 percent owner | Common Stock | 3,935 | $1.04 | $4,088 | ||
Option | SCHINAZI RAYMOND F 10 percent owner | Common Stock | 263,158 | $1.9 | $500,000 | ||
Option | SCHINAZI RAYMOND F 10 percent owner | 8% Convertible Note | 263,158 | $1.9 | $500,000 | ||
Option | SCHINAZI RAYMOND F 10 percent owner | Stock Options (Right to Buy) | 1,706,978 | $0.05 | $80,228 |
| Patent |
|---|
Application Filling date: 10 Sep 2019 Issue date: 24 Feb 2022 |
Application Filling date: 26 Nov 2019 Issue date: 17 Feb 2022 |
Application Filling date: 13 Nov 2019 Issue date: 23 Dec 2021 |
Application Filling date: 17 Oct 2019 Issue date: 18 Nov 2021 |
Application Filling date: 9 May 2019 Issue date: 3 Jun 2021 |
Grant Filling date: 24 Apr 2018 Issue date: 25 May 2021 |
Application Filling date: 26 Jul 2019 Issue date: 29 Apr 2021 |
Grant Filling date: 25 Sep 2019 Issue date: 16 Mar 2021 |
Application Filling date: 25 Sep 2019 Issue date: 13 Aug 2020 |
Application Filling date: 24 Apr 2018 Issue date: 23 Apr 2020 |
| Insider | Compensation |
|---|---|
Mr. James J. Martin CPA, CPA, M.B.A., MBA (1967) Interim Co-Chief Executive Officer, Chief Financial Officer & Corporation Sec. | $331,000 |
| Dr. Sam Lee (1960) Co-Founder, Interim Co-Chief Executive Officer & Pres | $313,000 |
| Dr. Roger D. Kornberg Ph.D. (1947) Co-Founder, Chairman & Scientific Advisory Board and Chief Scientist | $75,000 |
-
What's the price of Cocrystal Pharma stock today?
One share of Cocrystal Pharma stock can currently be purchased for approximately $1.53.
-
When is Cocrystal Pharma's next earnings date?
Unfortunately, Cocrystal Pharma's (COCP) next earnings date is currently unknown.
-
Does Cocrystal Pharma pay dividends?
No, Cocrystal Pharma does not pay dividends.
-
How much money does Cocrystal Pharma make?
Cocrystal Pharma has a market capitalization of 22.68M.
-
What is Cocrystal Pharma's stock symbol?
Cocrystal Pharma, Inc. is traded on the NASDAQ under the ticker symbol "COCP".
-
What is Cocrystal Pharma's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of Cocrystal Pharma?
Shares of Cocrystal Pharma can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Cocrystal Pharma's key executives?
Cocrystal Pharma's management team includes the following people:
- Mr. James J. Martin CPA, CPA, M.B.A., MBA Interim Co-Chief Executive Officer, Chief Financial Officer & Corporation Sec.(age: 58, pay: $331,000)
- Dr. Sam Lee Co-Founder, Interim Co-Chief Executive Officer & Pres(age: 65, pay: $313,000)
- Dr. Roger D. Kornberg Ph.D. Co-Founder, Chairman & Scientific Advisory Board and Chief Scientist(age: 78, pay: $75,000)
-
Is Cocrystal Pharma founder-led company?
Yes, Cocrystal Pharma is a company led by its founders Dr. Sam Lee and Dr. Roger D. Kornberg Ph.D..
-
How many employees does Cocrystal Pharma have?
As Jul 2024, Cocrystal Pharma employs 12 workers.
-
When Cocrystal Pharma went public?
Cocrystal Pharma, Inc. is publicly traded company for more then 13 years since IPO on 22 Feb 2012.
-
What is Cocrystal Pharma's official website?
The official website for Cocrystal Pharma is cocrystalpharma.com.
-
Where are Cocrystal Pharma's headquarters?
Cocrystal Pharma is headquartered at 19805 North Creek Parkway, Bothell, WA.
-
How can i contact Cocrystal Pharma?
Cocrystal Pharma's mailing address is 19805 North Creek Parkway, Bothell, WA and company can be reached via phone at +7 864591831.
Cocrystal Pharma company profile:
Cocrystal Pharma, Inc.
cocrystalpharma.comExchange:
NASDAQ
Full time employees:
12
Industry:
Biotechnology
Sector:
Healthcare
Cocrystal Pharma, Inc., a biotechnology company, focuses on the discovery and development of antiviral therapeutic treatments for serious and/or chronic viral diseases. It employs structure-based technologies to create antiviral drugs primarily to treat hepatitis C virus (HCV), influenza virus, coronavirus, and norovirus infections. The company develops CC-31244, a HCV non-nucleoside polymerase inhibitor that has completed Phase II a clinical trial to treat HCV infection; and CC-42344, a PB2 inhibitor that is in preclinical development trials for treating influenza infection. It is also involved in identifying and developing non-nucleoside polymerase inhibitors for norovirus infections. Cocrystal Pharma, Inc. has a license and research collaboration agreement with Merck Sharp & Dohme Corp. to discover and develop proprietary influenza A/B antiviral agents; a license agreement with Kansas State University Research Foundation to develop antiviral compounds for the treatment of norovirus and coronavirus infections; and drug discovery collaboration with HitGen and InterX Inc. The company is headquartered in Bothell, Washington.
19805 North Creek Parkway
Bothell, WA 98011
Bothell, WA 98011
CIK: 0001412486
ISIN: US19188J4094
CUSIP: 19188J300
